BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 35514210)

  • 1. Inhibition of pyrimidine biosynthesis targets protein translation in acute myeloid leukemia.
    So J; Lewis AC; Smith LK; Stanley K; Franich R; Yoannidis D; Pijpers L; Dominguez P; Hogg SJ; Vervoort SJ; Brown FC; Johnstone RW; McDonald G; Ulanet DB; Murtie J; Gruber E; Kats LM
    EMBO Mol Med; 2022 Jul; 14(7):e15203. PubMed ID: 35514210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Revisiting the role of dihydroorotate dehydrogenase as a therapeutic target for cancer.
    Madak JT; Bankhead A; Cuthbertson CR; Showalter HD; Neamati N
    Pharmacol Ther; 2019 Mar; 195():111-131. PubMed ID: 30347213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The novel dihydroorotate dehydrogenase (DHODH) inhibitor BAY 2402234 triggers differentiation and is effective in the treatment of myeloid malignancies.
    Christian S; Merz C; Evans L; Gradl S; Seidel H; Friberg A; Eheim A; Lejeune P; Brzezinka K; Zimmermann K; Ferrara S; Meyer H; Lesche R; Stoeckigt D; Bauser M; Haegebarth A; Sykes DB; Scadden DT; Losman JA; Janzer A
    Leukemia; 2019 Oct; 33(10):2403-2415. PubMed ID: 30940908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Patent Review of Human Dihydroorotate Dehydrogenase (hDHODH) Inhibitors as Anticancer Agents and their Other Therapeutic Applications (1999-2022).
    Gehlot P; Vyas VK
    Recent Pat Anticancer Drug Discov; 2024; 19(3):280-297. PubMed ID: 37070439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of Dihydroorotate Dehydrogenase Overcomes Differentiation Blockade in Acute Myeloid Leukemia.
    Sykes DB; Kfoury YS; Mercier FE; Wawer MJ; Law JM; Haynes MK; Lewis TA; Schajnovitz A; Jain E; Lee D; Meyer H; Pierce KA; Tolliday NJ; Waller A; Ferrara SJ; Eheim AL; Stoeckigt D; Maxcy KL; Cobert JM; Bachand J; Szekely BA; Mukherjee S; Sklar LA; Kotz JD; Clish CB; Sadreyev RI; Clemons PA; Janzer A; Schreiber SL; Scadden DT
    Cell; 2016 Sep; 167(1):171-186.e15. PubMed ID: 27641501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of mitochondrial complex III induces differentiation in acute myeloid leukemia.
    Zhang Y; Luo T; Ding X; Chang Y; Liu C; Zhang Y; Hao S; Yin Q; Jiang B
    Biochem Biophys Res Commun; 2021 Apr; 547():162-168. PubMed ID: 33610916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent developments in the medicinal chemistry and therapeutic potential of dihydroorotate dehydrogenase (DHODH) inhibitors.
    Vyas VK; Ghate M
    Mini Rev Med Chem; 2011 Oct; 11(12):1039-55. PubMed ID: 21861807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a biomarker to monitor target engagement after treatment with dihydroorotate dehydrogenase inhibitors.
    Pontikos MA; Leija C; Zhao Z; Wang X; Kilgore J; Tornesi B; Adenmatten N; Phillips MA; Williams NS
    Biochem Pharmacol; 2022 Oct; 204():115237. PubMed ID: 36055381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of Dihydroorotate Dehydrogenase Inhibitors Using the Cell Painting Assay.
    Schölermann B; Bonowski J; Grigalunas M; Burhop A; Xie Y; Hoock JGF; Liu J; Dow M; Nelson A; Nowak C; Pahl A; Sievers S; Ziegler S
    Chembiochem; 2022 Nov; 23(22):e202200475. PubMed ID: 36134475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DHODH: a promising target in the treatment of T-cell acute lymphoblastic leukemia.
    Sexauer AN; Alexe G; Gustafsson K; Zanetakos E; Milosevic J; Ayres M; Gandhi V; Pikman Y; Stegmaier K; Sykes DB
    Blood Adv; 2023 Nov; 7(21):6685-6701. PubMed ID: 37648673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The emergence of dihydroorotate dehydrogenase (DHODH) as a therapeutic target in acute myeloid leukemia.
    Sykes DB
    Expert Opin Ther Targets; 2018 Nov; 22(11):893-898. PubMed ID: 30318938
    [No Abstract]   [Full Text] [Related]  

  • 12. The Warburg effect modulates DHODH role in ferroptosis: a review.
    Amos A; Amos A; Wu L; Xia H
    Cell Commun Signal; 2023 May; 21(1):100. PubMed ID: 37147673
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Cisar JS; Pietsch C; DeRatt LG; Jacoby E; Kazmi F; Keohane C; Legenski K; Matico R; Shaffer P; Simonnet Y; Tanner A; Wang CY; Wang W; Attar R; Edwards JP; Kuduk SD
    J Med Chem; 2022 Aug; 65(16):11241-11256. PubMed ID: 35925768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel series of human dihydroorotate dehydrogenase inhibitors discovered by in vitro screening: inhibition activity and crystallographic binding mode.
    Zeng T; Zuo Z; Luo Y; Zhao Y; Yu Y; Chen Q
    FEBS Open Bio; 2019 Aug; 9(8):1348-1354. PubMed ID: 31087527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances on patents of
    Gehlot P; Vyas VK
    Expert Opin Ther Pat; 2023; 33(9):579-596. PubMed ID: 37942637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytarabine-induced differentiation of AML cells depends on Chk1 activation and shares the mechanism with inhibitors of DHODH and pyrimidine synthesis.
    Tomic B; Smoljo T; Lalic H; Dembitz V; Batinic J; Batinic D; Bedalov A; Visnjic D
    Sci Rep; 2022 Jul; 12(1):11344. PubMed ID: 35790845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of the de novo pyrimidine biosynthesis pathway limits ribosomal RNA transcription causing nucleolar stress in glioblastoma cells.
    Lafita-Navarro MC; Venkateswaran N; Kilgore JA; Kanji S; Han J; Barnes S; Williams NS; Buszczak M; Burma S; Conacci-Sorrell M
    PLoS Genet; 2020 Nov; 16(11):e1009117. PubMed ID: 33201894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Novel mechanism of herbicide action through disruption of pyrimidine biosynthesis.
    Kang IH; Emptage RP; Kim SI; Gutteridge S
    Proc Natl Acad Sci U S A; 2023 Nov; 120(48):e2313197120. PubMed ID: 37988466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ASLAN003, a potent dihydroorotate dehydrogenase inhibitor for differentiation of acute myeloid leukemia.
    Zhou J; Yiying Quah J; Ng Y; Chooi JY; Hui-Min Toh S; Lin B; Zea Tan T; Hosoi H; Osato M; Seet Q; Ooi LAG; Lindmark B; McHale M; Chng WJ
    Haematologica; 2020 Sep; 105(9):2286-2297. PubMed ID: 33054053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting Acute Myelogenous Leukemia Using Potent Human Dihydroorotate Dehydrogenase Inhibitors Based on the 2-Hydroxypyrazolo[1,5-
    Sainas S; Giorgis M; Circosta P; Gaidano V; Bonanni D; Pippione AC; Bagnati R; Passoni A; Qiu Y; Cojocaru CF; Canepa B; Bona A; Rolando B; Mishina M; Ramondetti C; Buccinnà B; Piccinini M; Houshmand M; Cignetti A; Giraudo E; Al-Karadaghi S; Boschi D; Saglio G; Lolli ML
    J Med Chem; 2021 May; 64(9):5404-5428. PubMed ID: 33844533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.